What is Scientus Pharma?
Scientus Pharma Inc. is a vertically-integrated biopharmaceutical company dedicated to the scientific research and commercialization of pharmaceutical-grade cannabinoid derivative products. Operating under the Cannabis Act and its Regulations as a Licensed Producer, and the Narcotics Control Act and its Regulations as a Licensed Dealer, the company is positioned at the intersection of pharmaceutical development and regulated cannabis markets. Its core mission involves advancing the therapeutic potential of cannabinoids through rigorous scientific inquiry and product development.
How much funding has Scientus Pharma raised?
Scientus Pharma has raised a total of $11.5M across 1 funding round:
Debt
$11.5M
Debt (2017): $11.5M with participation from Aphria Inc
Key Investors in Scientus Pharma
Aphria Inc
Aphria Inc., founded in 2014, is a Canadian-based producer, supplier, and seller of medical cannabis, indicating a strategic interest in the broader cannabinoid market and its pharmaceutical applications.
What's next for Scientus Pharma?
With a substantial enterprise-level funding context and a recent strategic investment, Scientus Pharma is poised for accelerated growth and development. This capital infusion is expected to fuel further research initiatives, expand its product pipeline, and potentially scale its manufacturing and commercialization efforts. The company's strategic positioning within the regulated cannabinoid market suggests a focus on clinical validation and market penetration for its pharmaceutical-grade derivatives, aiming to establish a strong foothold in a rapidly evolving therapeutic landscape.
See full Scientus Pharma company page
